Characterization of overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis according to antimitochondrial antibodies status

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 1, 2007, Pages 11-16

  Alric, Laurent ^a   Thebault, Sophie ^a   Selves, Janik ^a   Peron, Jean Marie ^a   Mejdoubi, Sanae ^a   Fortenfant, Françoise ^a   Vinel, Jean Pierre ^a  

^a CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; MITOCHONDRION ANTIBODY; PREDNISONE; SMOOTH MUSCLE ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT DISEASE; BILE DUCT INJURY; CHOLANGITIS; CLINICAL FEATURE; CLINICAL OBSERVATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OVERLAP SYNDROME; PRIMARY BILIARY CIRRHOSIS; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 33846839383     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)89322-5     Document Type: Article

References (24)

1. Alvarez A, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
2. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. New Engl J Med 2005;353:1261-73.
3. Lee YM, Kaplan M.M. Primary sclerosing cholangitis. New Engl J Med 1995;332:924-33.
4. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994;35:260-5.
5. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301.
6. Goodman ZD, McNally PR, Davis DR, Ishak KG. Auto-immune cholangitis: a variant of primary biliary cirrhosis. Dig Dis Sci 1995;40:1232-42.
7. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-5.
8. Lohse AW, Büschenfelde KHM, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-84.
9. Sherlock DS. Autoimmune cholangitis: a unique entity? Mayo Clin Proc 1998;73:184-90.
10. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and-negative primary biliary cirrhosis. Hepatology 1997;25:1090-5.
11. Brunner G, Klinge O. A cholangitis with antinuclear antibodies (immunocholangitis) resembling chronic non-suppurative destructive cholangitis. Deutsche Med Wochenschr 1987;112:1454-8.
12. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31:1231-8.
13. Krawitt E. Autoimmune hepatitis. New Engl J Med 2006;354:54-66.
14. Dubel L, Farges O, Bismuth H, Sebagh M, Homber JC, Johanet C. Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. J Hepatol 1995,23:674-80.
15. Alric L, Fort M, Izopet J, Vinel JP, Bureau C, Sandre K, et al. Study of host-and virus related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens 2000;56:154-8.
16. The METAVIR Cooperative Group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20:15-20.
17. Ludwig J, Dickson ER, McDonald GSA. Staging of chronic non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histopathol 1978;379:103-12.
18. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest associations. Tissue Antigens 1994;43:18-27.
19. Johnson PJ, McFarlane IG, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, et al. Meeting report. International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
20. Poupon RE, Poupon R, Balkau B, UCDA-PBC study group. Ursodiol for the long term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1386-7.
21. Joshi S, Gauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002;35:409-13.
22. Rodrigues CMP, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101:2790-9.
23. Calmus Y, Weill B, Ozier Y, Chéreau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 1992;103:617-21.
24. Duclos-Vallée JC, Di Martino V, Cazier A, Ballot E, Johanet C, Yamamoto AM, et al. Remission with ursodeoxycholic acid of type 1 autoimmune hepatitis resistant to azathioprine and steroids. Gastroenterol clin biol 2005;29:173-6.